Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI), recently spoke with i3 Health about the approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV. In this second installment of his interview, Dr. Yarchoan shares valuable advice with oncologists as they seek to enhance outcomes and treatment experiences for patients with Kaposi sarcoma. What advice can you share with oncologists treating patients with...

The treatment of gastrointestinal stromal tumor (GIST), a rare tumor type with an estimated incidence of 3,300 to 6,000 new cases per year in the United States, has seen exciting advances this year, first with the FDA's approval of avapritinib for metastatic GIST with platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, and more recently with last month's approval of ripretinib for the later-line treatment of metastatic GIST. Margaret von Mehren, MD, principal investigator o...

The FDA's recent accelerated approval of pomalidomide (Pomalyst®, Celgene) for Kaposi sarcoma in patients with and without HIV marked the first approval for this cancer in over 20 years. In this interview with i3 Health, Robert Yarchoan, MD, Chief of the HIV and AIDS Malignancy Branch at the National Cancer Institute (NCI) and principal investigator of the phase 1/2 Study 12-C-0047, which served as the basis for the approval, discusses pomalidomide's efficacy and safety, as well as additional re...

Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. In this interview with i3 Health, Margaret von Mehren, MD, lead investigator of the INVICTUS study, on which ripretinib's recent FDA approval was based, discusses how this treatment compares with other options for advanced GIST in terms of efficacy and adverse events. What are ...

The FDA has approved ripretinib (QinlockTM, Deciphera Pharmaceuticals, LLC) for adults with metastatic gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. Gastrointestinal stromal tumor is a rare tumor type with a yearly incidence of around 4,000 to 6,000 in the United States. "Despite the progress that has been made over the past 20 years in developing treatments for GIST, including four FDA-approved targeted therapies––imatinib in...